The global lyme disease diagnostic devices market size was USD 2.53 billion in 2023, calculated at USD 2.67 billion in 2024 and is expected to reach around USD 4.56 billion by 2034, expanding at a CAGR of 5.5% from 2024 to 2034.
The global lyme disease diagnostic devices market size accounted for USD 2.67 billion in 2024 and is expected to reach around USD 4.56 billion by 2034, expanding at a CAGR of 5.5% from 2024 to 2034. The North America lyme disease diagnostic devices market size reached USD 1.01 billion in 2023.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. lyme disease diagnostic devices market size was estimated at USD 710 million in 2023 and is predicted to be worth around USD 1,310 million by 2034, at a CAGR of 5.7% from 2024 to 2034.
North America is Estimated to be the Largest Market for Lyme Disease Diagnostic Devices
The research report covers key trends and prospects of Lyme disease diagnostic devices products across different geographical regions including North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Geographically, Lyme disease diagnostic devices market is conquered by North America owing to high incidence of Lyme disease and existence of state-of-the-art healthcare infrastructure. On the other hand, Asia-Pacific is anticipated to witness the rapid growth rate, on account of increasing research and development investment by major market players and increasing awareness regarding tick-borne infectious disorders.
Upsurge in incidence of Lyme disease, growing policy attention on improving health care services, and the advent of new diagnostic tests for Lyme disease pushes the market. Nonetheless, lack of knowledge of the disease and ineffectiveness in Lyme disease research reduces the market. Additionally, growth in key players’ interests in Lyme disease diagnosis R&D is predicted to provide lucrative business growth opportunities. Moreover, increasing number of cases of tick-borne infectious diseases is boosting Lyme disease diagnostics market. Vector-borne diseases are illnesses caused by pathogens and parasites in human inhabitants. Each year greater than 1 billion individuals are infected and higher than 1 million people die from vector-borne illnesses. They can be infected by bacteria, parasites or viruses. More than 16% of the ailment and disability endured globally is because of vector-borne illnesses, with more than 50% of world’s population presently assessed to be at risk of these ailments.
| Report Highlights | Details |
| Market Size in 2023 | USD 2.53 billion |
| Market Size in 2024 | USD 2.67 billion |
| Market Size by 2034 | USD 4.56 billion |
| Growth Rate from 2024 to 2034 | CAGR of 5.5% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2023 |
| Forecast Period | 2024 to 2034 |
| Segments Covered | Product, End User, Region |
| Regions Covered | North America, Asia Pacific, Europe, Latin America, Middle East and Africa |
Serological Test Segment Reported Foremost Market Stake in 2023
Serological test segment recorded the prime market share in the global Lyme disease diagnostic devices market by type in 2023. Increasing use in the early diagnosis of Lyme disease diagnostics is the major reason for high market share of serological test. Other factors such as increasing investment in research and development is expected to increase the usage of serological tests over the estimate period.
The lymphocytic transformation tests are projected grow at the highest CAGR during the forecast period mainly due to new product launches in the near future.
Hospitals are Projected to Dominate the End User Segment of Lyme Disease Diagnostic Devices Market Revenue
The Lyme disease diagnosis is based on infection signs and symptoms, history of exposures to infected black-legged ticks, and laboratory tests. Serological tests can take several weeks to become conclusive after infection, indicating the need for new diagnostic tests that can identify the earliest signs of infection. Hospitals are well-equipped to handle patient flow and employ latest diagnostic and treatment techniques. These factors are primarily responsible for the greater market share of hospitals in the end-user segment of the Lyme Disease Diagnostic Devices Market.
Public/private laboratories segment will expand at a significant CAGR during the forecast time-frame.
Major Market Segments Covered
By Product Type
By End User
By Geography
Lyme Disease Diagnostic Devices Market
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Lyme Disease Diagnostic Devices Market
5.1. COVID-19 Landscape: Lyme Disease Diagnostic Devices Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Lyme Disease Diagnostic Devices Market, By Product Type
8.1. Lyme Disease Diagnostic Devices Market, by Product Type, 2024-2034
8.1.1. Serological Test
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Urine Antigen Tests
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Lymphocytic Transformation Test
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Immunofluorescent Staining
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Nucleic acid Test
8.1.5.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Lyme Disease Diagnostic Devices Market, By End User
9.1. Lyme Disease Diagnostic Devices Market, by End User, 2024-2034
9.1.1. Hospitals
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Public/Private Laboratories
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Physician’s Office
9.1.3.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Lyme Disease Diagnostic Devices Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Product Type (2021-2034)
10.1.2. Market Revenue and Forecast, by End User (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Product Type (2021-2034)
10.1.3.2. Market Revenue and Forecast, by End User (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Product Type (2021-2034)
10.1.4.2. Market Revenue and Forecast, by End User (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product Type (2021-2034)
10.2.2. Market Revenue and Forecast, by End User (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Product Type (2021-2034)
10.2.3.2. Market Revenue and Forecast, by End User (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Product Type (2021-2034)
10.2.4.2. Market Revenue and Forecast, by End User (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Product Type (2021-2034)
10.2.5.2. Market Revenue and Forecast, by End User (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Product Type (2021-2034)
10.2.6.2. Market Revenue and Forecast, by End User (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product Type (2021-2034)
10.3.2. Market Revenue and Forecast, by End User (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Product Type (2021-2034)
10.3.3.2. Market Revenue and Forecast, by End User (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Product Type (2021-2034)
10.3.4.2. Market Revenue and Forecast, by End User (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Product Type (2021-2034)
10.3.5.2. Market Revenue and Forecast, by End User (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Product Type (2021-2034)
10.3.6.2. Market Revenue and Forecast, by End User (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product Type (2021-2034)
10.4.2. Market Revenue and Forecast, by End User (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Product Type (2021-2034)
10.4.3.2. Market Revenue and Forecast, by End User (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Product Type (2021-2034)
10.4.4.2. Market Revenue and Forecast, by End User (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Product Type (2021-2034)
10.4.5.2. Market Revenue and Forecast, by End User (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Product Type (2021-2034)
10.4.6.2. Market Revenue and Forecast, by End User (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product Type (2021-2034)
10.5.2. Market Revenue and Forecast, by End User (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Product Type (2021-2034)
10.5.3.2. Market Revenue and Forecast, by End User (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Product Type (2021-2034)
10.5.4.2. Market Revenue and Forecast, by End User (2021-2034)
Chapter 11. Company Profiles
11.1. Bio-Rad Laboratories, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Thermo Fisher Scientific, Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Boulder Diagnostics
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. T2 Biosystems, Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Abbott
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Oxford Immunotec Global PLC
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Quidel Corporation
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Affymetrix Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Hoffmann-La Roche Ltd
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Graphene Frontiers
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample